Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756)

Expert Opin Ther Pat. 2012 Jun;22(6):709-13. doi: 10.1517/13543776.2012.691968. Epub 2012 May 21.

Abstract

Scientific evaluation of a patent aiming for the development of pyrazolopyridine derivatives as LRRK2 kinase inhibitors, a potential therapeutic target for combating Parkinson's disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparkinson Agents / chemistry
  • Antiparkinson Agents / pharmacology*
  • Drug Design*
  • Humans
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
  • Molecular Structure
  • Patents as Topic
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Protein Serine-Threonine Kinases / metabolism
  • Pyrazoles / chemistry
  • Pyrazoles / pharmacology*
  • Pyridines / chemistry
  • Pyridines / pharmacology*
  • Structure-Activity Relationship

Substances

  • Antiparkinson Agents
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • pyrazolopyridine
  • LRRK2 protein, human
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
  • Protein Serine-Threonine Kinases